Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2024)
Historic Operating Expenses for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to $12.9 million.
- Inhibikase Therapeutics' Operating Expenses rose 19359.61% to $12.9 million in Q4 2024 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 3556.25%. This contributed to the annual value of $28.6 million for FY2024, which is 4048.48% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported Operating Expenses of $12.9 million as of Q4 2024, which was up 19359.61% from $5.8 million recorded in Q3 2024.
- Over the past 5 years, Inhibikase Therapeutics' Operating Expenses peaked at $12.9 million during Q4 2024, and registered a low of $633506.0 during Q2 2020.
- Moreover, its 5-year median value for Operating Expenses was $4.7 million (2022), whereas its average is $4.4 million.
- As far as peak fluctuations go, Inhibikase Therapeutics' Operating Expenses skyrocketed by 58428.49% in 2021, and later plummeted by 2007.14% in 2024.
- Inhibikase Therapeutics' Operating Expenses (Quarter) stood at $1.4 million in 2020, then soared by 267.79% to $5.0 million in 2021, then fell by 12.79% to $4.4 million in 2022, then rose by 0.11% to $4.4 million in 2023, then skyrocketed by 193.6% to $12.9 million in 2024.
- Its last three reported values are $12.9 million in Q4 2024, $5.8 million for Q3 2024, and $5.1 million during Q2 2024.